Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Extramedullary Disease Is Common In Newly Diagnosed AML But Has No Independent Prognostic Significance, Including CNS Involvement: Analysis Of 3,522 AML Patients Treated On Consecutive ECOG Trials 1980-2008

Chezi Ganzel, MD, Judith Manola, MS, Dan Douer, MD, Jacob M. Rowe, MD, Hugo F Fernandez, MD, Elisabeth Paietta, Ph.D, Mark R. Litzow, MD, Ju-Whei Lee, Selina M Luger, MD, Hillard M. Lazarus, MD, Larry Cripe, MD, Martin M Oken, MD, Peter A Cassileth, MD, Martin S. Tallman, MD

Blood (2013) 122 (21): 63.

https://doi.org/10.1182/blood.V122.21.63.63

Published: 2013

Journal Articles

Characterization of FLT3 Pathway Deregulation by Single Cell Network Profiling (SCNP) Stratifies AML Patients Beyond Molecular Profiling

David B. Rosen, PhD, Santosh Putta, Ph.D., Urte Gayko, Ph.D., Alessandra Cesano, MD, Larry Cripe, MD, Zhuoxin Sun, PhD, Mark R. Litzow, MD, Hajime Uno, PhD, Martin S. Tallman, MD, Elisabeth Paietta, PhD

Blood (2010) 116 (21): 2739.

https://doi.org/10.1182/blood.V116.21.2739.2739

Published: 2010

Journal Articles

Cyclic Administration of Combination of Sorafenib and Vorinostat In Poor-Risk AML: A Pharmacodynamically-Oriented Extended Phase I Trial

Hamid Sayar, MD, Larry Cripe, MD, Mary Cangany, Jill Weisenbach, RN, OCN, Katie J. Sargent, RN, Chirayu Goswami, PhD., Lang Li, PhD., Annique Wilson-Weekes, MS, Rajasubramaniam Shanmugam, PhD, H. Scott Boswell, MD

Blood (2010) 116 (21): 3272.

https://doi.org/10.1182/blood.V116.21.3272.3272

Published: 2010

Journal Articles

A Pathway-focused GSEA Platform In AML That Interrogates Interaction of Flt3ITD and tMLL with Their Epigenetic Targets (p16INK4a, DAPK1, and RUNX3), While Accurately Reporting Broad-based AML Prognosis and Targeting-agent Sensitivity.

Tareq Al Baghdadi, MD, Chirayu Goswami, PhD., Hamid Sayar, MD, Katie J. Sargent, RN, Larry Cripe, MD, Lang Li, PhD., Rajasubramaniam Shanmugam, H. Scott Boswell, MD

Blood (2010) 116 (21): 1660.

https://doi.org/10.1182/blood.V116.21.1660.1660

Published: 2010

Journal Articles

Specimen Source (BM or PB) Does Not Affect Proteomic Signaling In Patients with AML and Circulating Blasts

Alessandra Cesano, MD, David B. Rosen, PhD, Santosh Putta, Urte Gayko, Ph.D., Larry Cripe, MD, Zhuoxin Sun, PhD, Hajime Uno, PhD, Mark R. Litzow, MD, Martin S. Tallman, MD, Elisabeth Paietta, PhD

Blood (2010) 116 (21): 2693.

https://doi.org/10.1182/blood.V116.21.2693.2693

Published: 2010

Journal Articles

Single-Cell Network Profiliing (SCNP) Signatures Independently Predict Response to Induction Therapy In Older Patients with Acute Myeloid Leukemia (AML)

Alessandra Cesano, MD, Santosh Putta, Ph.D., Urte Gayko, Ph.D., James Hackett, Ph.D., David B. Rosen, PhD, Larry Cripe, MD, Zhuoxin Sun, PhD, Hajime Uno, PhD, Mark R. Litzow, MD, Martin S. Tallman, MD, Elisabeth Paietta, PhD

Blood (2010) 116 (21): 2695.

https://doi.org/10.1182/blood.V116.21.2695.2695

Published: 2010

Journal Articles

A 3,239 -Patient Combined Eastern Cooperative Oncology Group (ECOG), M.D. Anderson Cancer Center (MDA) Analysis of the Effect of CR vs. Responses < CR on Long-Term Survival in Newly-Diagnosed AML Treated with Ara-C-Containing Regimens: Implications for Targeted Drug Development.

Elihu Estey, MD, Zhuoxin Sun, MD, Jacob Rowe, MD, Stefan Faderl, MD, Peter Cassileth, MD, George Sartiano, MD, Anthony Tartaglia, MD, Guillermo Garcia-Manero, MD, Larry Cripe, MD, John Bennett, MD, Hagop Kantarjian, MD, Martin Tallman, MD

Blood (2007) 110 (11): 298.

https://doi.org/10.1182/blood.V110.11.298.298

Published: 2007

Journal Articles

A Randomized, Open-Label Study of Lestaurtinib (CEP-701), an Oral FLT3 Inhibitor, Administered in Sequence with Chemotherapy in Patients with Relapsed AML Harboring FLT3 Activating Mutations: Clinical Response Correlates with Successful FLT3 Inhibition.

Mark Levis, MD, PhD, B. Douglas Smith, MD, Miloslav Beran, MD, Maria R. Baer, MD, Harry P. Erba, MD, Larry Cripe, MD, Steven Coutre, MD, Anjali Advani, MD, Alexander Perl, MD, Marcel Devetten, MD, Robert Stuart, MD, Martin S. Tallman, MD, Peter Brown, PhD, Lothar Tremmel, Donald Small, MD, PhD

Blood (2005) 106 (11): 403.

https://doi.org/10.1182/blood.V106.11.403.403

Published: 2005

NARROW

Extramedullary Disease Is Common In Newly Diagnosed AML But Has No Independent Prognostic Significance, Including CNS Involvement: Analysis Of 3,522 AML Patients Treated On Consecutive ECOG Trials 1980-2008

Characterization of FLT3 Pathway Deregulation by Single Cell Network Profiling (SCNP) Stratifies AML Patients Beyond Molecular Profiling

Cyclic Administration of Combination of Sorafenib and Vorinostat In Poor-Risk AML: A Pharmacodynamically-Oriented Extended Phase I Trial

A Pathway-focused GSEA Platform In AML That Interrogates Interaction of Flt3ITD and tMLL with Their Epigenetic Targets (p16INK4a, DAPK1, and RUNX3), While Accurately Reporting Broad-based AML Prognosis and Targeting-agent Sensitivity.

Specimen Source (BM or PB) Does Not Affect Proteomic Signaling In Patients with AML and Circulating Blasts

Single-Cell Network Profiliing (SCNP) Signatures Independently Predict Response to Induction Therapy In Older Patients with Acute Myeloid Leukemia (AML)

A 3,239 -Patient Combined Eastern Cooperative Oncology Group (ECOG), M.D. Anderson Cancer Center (MDA) Analysis of the Effect of CR vs. Responses < CR on Long-Term Survival in Newly-Diagnosed AML Treated with Ara-C-Containing Regimens: Implications for Targeted Drug Development.

A Randomized, Open-Label Study of Lestaurtinib (CEP-701), an Oral FLT3 Inhibitor, Administered in Sequence with Chemotherapy in Patients with Relapsed AML Harboring FLT3 Activating Mutations: Clinical Response Correlates with Successful FLT3 Inhibition.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only